S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
NASDAQ:AVTX

Avalo Therapeutics (AVTX) Price Target & Analyst Ratings

$2.71
-0.09 (-3.21%)
(As of 02:19 PM ET)
Compare
Today's Range
$2.71
▼
$2.83
50-Day Range
$1.61
▼
$3.40
52-Week Range
$1.41
▼
$7.41
Volume
4,555 shs
Average Volume
36,986 shs
Market Capitalization
$35.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Avalo Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Reduce
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$15.50
471.96% Upside
High Prediction$21.00
Average Prediction$15.50
Low Prediction$10.00
TypeCurrent
6/2/22 to 6/2/23		1 Month Ago
5/3/22 to 5/3/23		3 Months Ago
3/4/22 to 3/4/23		1 Year Ago
6/2/21 to 6/2/22
Consensus Rating
Reduce
Reduce
Reduce
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.50$15.50$15.50$39.00
Predicted Upside471.96% Upside194.96% Upside194.96% Upside274.71% Upside
Get Avalo Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.


AVTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avalo Therapeutics Stock vs. The Competition

TypeAvalo TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
1.00
2.66
2.49
Consensus RatingReduceBuyHold
Predicted Upside471.96% Upside1,254.16% Upside200.05% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeHold ➝ Underperform
11/15/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$10.00+72.41%
7/11/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$24.00 ➝ $21.00+345.86%
(Data available from 6/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AVTX Price Target - Frequently Asked Questions

What is Avalo Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Avalo Therapeutics stock is Reduce based on the current 1 sell rating for AVTX. The average twelve-month price prediction for Avalo Therapeutics is $15.50 with a high price target of $21.00 and a low price target of $10.00. Learn more on AVTX's analyst rating history.

Do Wall Street analysts like Avalo Therapeutics more than its competitors?

Analysts like Avalo Therapeutics less than other Medical companies. The consensus rating for Avalo Therapeutics is Reduce while the average consensus rating for medical companies is Buy. Learn more on how AVTX compares to other companies.

Does Avalo Therapeutics's stock price have much upside?

According to analysts, Avalo Therapeutics's stock has a predicted upside of 194.96% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:AVTX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -